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Abstract
Amyotrophic lateral sclerosis (ALS) is a progressive, neurodegenerative disease characterized by loss of upper and lower motor
neurons. ALS is considered to be a complex trait and genome-wide association studies (GWAS) have implicated a few susceptibility
loci. However, many more causal loci remain to be discovered. Since it has been shown that genetic variants associated with
complex traits are more likely to be eQTLs than frequency-matched variants from GWAS platforms, we conducted a two-stage
genome-wide screening for eQTLs associated with ALS. In addition, we applied an eQTL analysis to finemap association loci.
Expression profiles using peripheral blood of 323 sporadic ALS patients and 413 controls were mapped to genome-wide
genotyping data. Subsequently, data from a two-stage GWAS (3,568 patients and 10,163 controls) were used to prioritize eQTLs
identified in the first stage (162 ALS, 207 controls). These prioritized eQTLs were carried forward to the second sample with both
gene-expression and genotyping data (161 ALS, 206 controls). Replicated eQTL SNPs were then tested for association in the
second-stage GWAS data to find SNPs associated with disease, that survived correction for multiple testing. We thus identified
twelve cis eQTLs with nominally significant associations in the second-stage GWAS data. Eight SNP-transcript pairs of highest
significance (lowest p=1.27610251) withstood multiple-testing correction in the second stage and modulated CYP27A1 gene
expression. Additionally, we show that C9orf72 appears to be the only gene in the 9p21.2 locus that is regulated in cis, showing the
potential of this approach in identifying causative genes in association loci in ALS. This study has identified candidate genes for
sporadic ALS, most notably CYP27A1. Mutations in CYP27A1 are causal to cerebrotendinous xanthomatosis which can present as a
clinical mimic of ALS with progressive upper motor neuron loss, making it a plausible susceptibility gene for ALS.
Citation: Diekstra FP, Saris CGJ, van Rheenen W, Franke L, Jansen RC, et al. (2012) Mapping of Gene Expression Reveals CYP27A1 as a Susceptibility Gene for
Sporadic ALS. PLoS ONE 7(4): e35333. doi:10.1371/journal.pone.0035333
Editor: Marcel P. van der Brug, Genentech, United States of America
Received December 20, 2011; Accepted March 13, 2012; Published April 11, 2012
Copyright:  2012 Diekstra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Prinses Beatrix Fonds (Kersten Foundation); VSB fonds; The Netherlands ALS Foundation and J.R. van Dijk; and the
Adessium Foundation to [LHB]. JHV is supported by the Brain Foundation of The Netherlands; and the Thierry Latran Foundation. The GWA study was funded by the
Netherlands Organization of Scientific Research NWO Investments [grant numbers 175.010.2005.011, 911-03-012]; the Research Institute for Diseases in the Elderly
(014-93-015; RIDE); and the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO) [project number 050-060-810]. In addition,
the research leading to these results has received funding from the European Community’s Health Seventh Framework Programme (FP7/2007-2013) [grant
agreement number 259867]. SH is supported by National Institutes of Health [grant numbers IU19A1063603-01, 5P30CA016042-28, P50CA092131, and DK072206].
The Rotterdam Study is funded by Erasmus Medical Center and Erasmus University, Rotterdam; Netherlands Organization for the Health Research and Development
(ZonMw); the Research Institute for Diseases in the Elderly (RIDE); the Ministry of Education, Culture and Science; the Ministry for Health, Welfare and Sports; the
European Commission (DG XII); and the Municipality of Rotterdam. The Irish study was funded by The Muscular Dystrophy Association (USA); The Health Research
Board of Ireland; The Irish Neurological Association Travel Award; and The Irish Motor Neuron Disease Research Foundation. In Sweden, this project was supported by
the Swedish Brain Research Foundation; the Ha˚llstens Research Foundation; the Swedish Medical Society; the Bjo¨rklund Foundation for ALS Research; and the
Swedish Association for the Neurologically Disabled to [PMA]. WR was supported by grants from the University of Leuven (Methusalem); and the Interuniversity
Attraction Poles program P6/43 of the Belgian Federal Science Policy Office. In France, this study was funded by the Association pour la Recherche sur la SLA; and the
Association Re´seau SLA Ile de France. Support was also provided by the ALS Therapy Alliance; Project ALS; the Angel Fund; the Pierre L. de Bourgknecht ALS Research
Foundation; the Al-Athel ALS Research Foundation; the ALS Family Charitable Foundation and the National Institute of Neurological Disorders and Stroke
[NS050557].’’ The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35333
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: j.h.veldink@umcutrecht.nl
. These authors contributed equally to this work.
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative
disease characterized by progressive muscle weakness caused by
loss of central and peripheral motor neurons. Symptoms typically
have a localized limb or bulbar onset and progress to other muscle
groups of the body. Denervation of respiratory muscles and
dysphagia leading to respiratory complications are the most
common causes of death. There is no cure for this rapidly
progressive disease.
Approximately 5% of patients have a family history of ALS [1].
All other cases are considered to have a sporadic form of the
disease. ALS is considered to be a disease of complex etiology with
both genetic and environmental factors contributing to disease
susceptibility [2]. These genetic factors are the subject of extensive
research [3]. Multiple genome-wide association studies (GWAS)
and candidate gene studies have been carried out, implicating
several genes in the susceptibility to ALS [4–8], but attempts to
replicate most of these genes have proven difficult [9–13].
Recently, our group has published a GWAS comprising over
4,800 patients and nearly 15,000 controls and identifying UNC13A
and 9p21.2 as susceptibility loci for sporadic ALS [7]. The 9p21.2
locus was recently replicated in an independent set of British
patients and controls [12] and also shown to be strongly associated
with ALS in Finland [14]. This locus was previously found to be
one of the linked loci in families with ALS and frontotemporal
dementia (FTD), and it was recently shown that a hexanucleotide
repeat expansion in C9orf72 was the basis of this linkage signal
[15,16].
Despite these large study samples, GWAS have been able to
explain only little of the genetic variation in ALS [4–7]. An
important drawback of GWAS is the burden of multiple-testing
correction, requiring even larger sample sizes in order to be able to
detect small effects. It is common practice to apply a strict
Bonferroni correction to GWAS data. With so many tests, there is
a high false-negative rate, as true associations are hidden in the fog
of random associations.
It has been established that gene expression levels can be
mapped to genomic variation as a quantitative trait in order to
detect so-called expression quantitative trait loci (eQTLs) [17–19].
Recently, it has been shown that trait-associated SNPs are more
likely to be eQTLs [20], making the systematic analysis of eQTLs
in the context of a GWAS a promising tool for the discovery of
novel disease-causing genes. In addition, eQTLs can have local
and distant effects, allowing for the identification of parts of
biological networks related to disease. These networks might be
the link between several different genetic variants that appear to be
associated with a disease in a GWAS [19]. In practical terms, in
order to identify eQTLs associated with disease, both genome-
wide genotype data as well as genome-wide gene expression levels
have to be collected. The focused genetic mapping of gene
expression levels has frequently been applied to the fine-mapping
of risk loci resulting from GWAS, for example in the study of
asthma [21] and Crohn’s disease [22]. Furthermore, genome-wide
eQTL analysis has proven fruitful in the study of diseases including
obesity [23], hypercholesterolemia [24], celiac disease [25], and
late-onset Alzheimer disease [26]. In the present study, we have
performed a genome-wide screen for eQTLs associated with
susceptibility to ALS.
A schematic overview of our study design is shown in Figure 1.
We performed an initial screen for eQTLs in an eQTL discovery
set. The eQTL SNPs resulting from this screen that had a
nominally significant effect in a discovery set from our previously
published GWAS [7] were selected for follow-up in the eQTL
replication set. Ultimately, replicated eQTLs were tested for
significant effects in the GWAS replication data, correcting for
multiple testing.
Methods
Ethics Statement
All participants gave written informed consent and approval
was obtained from the Institutional Review Board of the
University Medical Center Utrecht. The present study was
conducted according to the principles expressed in the Declaration
of Helsinki.
GWAS Data
Genome-wide genotype data were derived from a previously
published GWAS of sporadic ALS in seven countries (The
Netherlands, Belgium, France, Ireland, United Kingdom, Sweden,
United States) [7]. All patients fulfilled the 1994 El Escorial criteria
for probable or definite ALS [27]. Cohorts for which genome-wide
SNP data were available were included. For both the discovery
and replication set, genotype files with Illumina Beadchip data
(HumanHap 300K, HumanCNV 370K, HumanHap 550K or
HumanHap 610K platforms) were merged and the following
quality control measures were taken. Only SNPs common to all
cohorts were used. Triallelic and C/G or A/T SNPs were
excluded. Genotype files were merged, and after each merge, a
flipscan (scan for possible allele swaps) was performed in PLINK
Figure 1. Study design. For each step, the number of resulting SNP-
transcript pairs in cis is shown.
doi:10.1371/journal.pone.0035333.g001
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v1.07 [28]. SNPs with call rate ,95%, minor allele frequency
,5%, deviation from Hardy-Weinberg equilibrium in controls
(p,161024), or with differing heterozygosity or missing rates
between cases and controls were excluded. Duplicate samples,
samples with a genotyping rate ,95%, samples without gender
information, or samples where the genotypic gender did not match
the phenotype file gender were excluded. LD-based SNP pruning
was used to determine a subset of SNPs in approximate linkage
equilibrium. This subset of SNPs was used to identify related
samples, which were subsequently removed (pi-hat .0.2). The
software package EIGENSTRAT was used to detect population
substructure by principal components analysis [29]. HapMap
phase III release 2 genotypes were added into this analysis in order
to determine population outliers. After removal of population
outliers, new principal components were calculated. More detailed
data on included subjects, genotyping methods, and quality
control are available in Text S1 and Table S5.
Expression Data
Genome-wide gene expression data were obtained from 805
Dutch individuals (357 patients and 448 controls), who were also
genotyped on either the HumanHap 300K, HumanCNV 370K or
HumanHap 550K platforms in the previously described GWAS
[7]. Patients were recruited at our referral clinic for motor neuron
disease at the University Medical Center Utrecht, The Nether-
lands. Included patients were diagnosed with probable or definite
sporadic ALS according to the 1994 El Escorial criteria [27].
Messenger RNA was collected and extracted from peripheral
whole blood using PAXgene tubes and PAXgene extraction kit
(Qiagen). Samples were hybridized to Illumina HumanHT-12v3
Expression BeadChips. Case and control samples were randomly
assigned to the chips and all chips were run in one batch. Before
quality control, expression levels were available for 48,803 probes.
Raw expression data were quantile normalized and log2
transformed [30] in R (2009, The R Foundation for Statistical
Computing). Using principal components analysis of expression
data, outlier arrays were detected. Non-pseudoautosomal Y
chromosome transcript expression levels were used for a gender
check. Outlier arrays, samples with inconsistent gender informa-
tion, and samples designated as duplicates in our GWAS data,
were removed from the raw data (n = 67). Also, non-autosomal
probes were excluded (n = 2,002). The thus obtained trimmed raw
dataset was again quantile normalized and log2 transformed. All
probe sequences were aligned to the NCBI build 36 reference
genome using UCSC’s Genome Browser function BLAT [31].
Non-specific probes, defined as no or multiple hits with a sequence
homology .95%, were removed (n= 7,234). RefSeq (updated on
27 September 2010) and UniGene (build #228, release date 29
October 2010) databases were used to determine probes mapping
to transcripts designated as retired and these probes were excluded
as well (n = 2,449), leaving 37,118 gene-expression probes.
eQTL Datasets
For the genetic mapping of gene expression, the subset of Dutch
individuals with both genome-wide genotype and expression data
was tested for population substructure by principal components
analysis of genomic data using EIGENSTRAT [29]. By inspecting
the first two principal components, two outlier samples (one case,
one control) were identified and excluded. Subsequently, new
principal components were calculated. Non-autosomal SNPs were
removed from the eQTL analysis. We randomly split our
expression dataset to form equally sized discovery and replication
sets (Table S1).
Statistical Analysis
For the GWAS data, association with disease was tested in a
logistic model using gender, dummy-coded nationality and the first
eight principal components in order to correct for ancestry as
covariates. To determine the number of principal components to
be included in the logistic regression model, the first ten principal
components from the EIGENSTRAT [29] analysis were tested for
association with case/control status (threshold p,0.05). For the
GWAS discovery set, eight principal components were included in
the logistic model, while for the GWAS replication set two
principal components were included. Analyses were performed in
PLINK v1.07 [28] and R (2009, The R Foundation for Statistical
Computing).
For all analyses involving expression data, Surrogate Variable
Analysis (SVA) was used to account for heterogeneity in gene
expression due to known and unknown environmental, technical
or demographic factors [32]. SVA captures these factors into
covariates for use in statistical models. Additionally, ‘riluzole use’
status was obtained, the only drug available to ALS patients with
proven effect on survival.
For the eQTL analyses, SNP genotypes coded as an additive
genetic model were tested for association with gene expression by
linear regression using disease status, age, gender, surrogate
variables (18 in the discovery set and 19 in the replication) and
riluzole use as covariates. Cis eQTLs were defined as SNPs
modulating transcript expression levels within a region of 1Mb
surrounding a probe’s genomic midpoint [26]. False-positive cis
effects may, however, occur due to SNPs that are located within a
transcript probe or that are in linkage disequilibrium (LD) with
SNPs mapping within a transcript probe [33]. We used the Broad
Institute SNAP tool v2.2 [34] to determine pairwise LD between
cis effect SNPs and SNPs mapping to a transcript probe in either of
the HapMap phase III release 2 or 1000 Genomes Pilot 1 CEU
panels. 21,863 SNP-transcript combinations (pairwise LD thresh-
old r2 .0.2) were excluded from analysis. Similarly, we removed
24,170 SNP-transcript combinations with an InDel overlapping
with a transcript probe, according to the Database of Genomic
Variants (version 10, November 2010) [35]. There were 3,541,781
possible SNP-transcript combinations in cis left for analysis. The
number of possible combinations in cis was used for Benjamini-
Hochberg false discovery rate (FDR) calculations. Significant cis
effects were those SNP-transcript pairs that had significant p
values at an FDR of 5% after 10,000 permutations. Permutations
were performed swapping case/controls labels so that each subject
is assigned the genotype vector of another random subject, while
the expression matrix is unchanged. This prevents the underes-
timation of the null distribution, thereby preventing the detection
of false-positive eQTLs, as described previously [36]. Analyses
were performed in PLINK [28] and R (2009, The R Foundation
for Statistical Computing).
eQTL Selection
In order to link the identified eQTLs to disease, we made a
selection of significant cis effects in the eQTL discovery set. Recent
studies on the genetics of gene expression have shown that disease-
associated loci from GWAS are greatly enriched for eQTLs
[20,25]. Thus, we selected SNP-transcript pairs that had a
nominal SNP p value ,0.05 in our GWAS discovery data
(Figure 1).
Only these SNP-transcript pairs were used for follow-up in the
replication data. Patient characteristics for the expression
replication dataset are presented in Table S1. SNP genotypes
were correlated to gene expression levels following a similar
Mapping of Gene Expression in Sporadic ALS
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statistical analysis as used for our discovery set. Again, a 5% FDR
significance threshold was applied.
Subsequently, association with ALS for SNPs from the
replicated cis SNP-transcript pairs was tested in the GWAS
replication data by logistic regression using gender, dummy-coded
nationality and the first two EIGENSTRAT principal components
(these were significantly correlated to case/control status) as
covariates. Association test results were clumped based on LD (r2
.0.5) using PLINK, so that SNP p values could be obtained for
independent eQTLs. eQTLs with a replication pGWAS,0.05 after
Bonferroni correction for the number of independent (LD-based
clumped) loci were considered to be significant (Figure 1).
Results
eQTL Discovery
After quality control, eQTL analyses were performed on
162 ALS cases and 207 controls in the eQTL discovery set with
data on 261,682 autosomal SNPs and 37,118 expression probes.
Patient characteristics are summarized in Table S1. At a
Benjamini and Hochberg false discovery rate (FDR) of 5%, we
detected 16,901 significant SNP-transcript pairs in cis (Figure 1).
GWAS Discovery
In the GWAS discovery set, 2,261 ALS cases and 8,328 patients
remained after quality control measures with genotypes for
268,952 SNPs. Details of included study populations are shown
in Table S2. Association analysis resulted in one SNP (rs12608932
in gene UNC13A) with genome-wide significance (p = 1.7610–8)
after Bonferroni correction for 268,952 SNPs. A Manhattan plot
of genome-wide results is shown in Figure S1. A quantile-quantile
plot of disease association p values is provided in Figure S2
(genomic control l=1.03). There were 14,167 autosomal SNPs
with a nominal p value ,0.05. These SNPs were used to prioritize
eQTLs found in the eQTL discovery set (Figure 1).
From the eQTL discovery results, we selected the 1,108 SNP-
transcript pairs (755 eQTL SNPs) in cis with discovery pGWAS
,0.05 (Figure 1). To confirm the hypothesis that disease-
associated SNPs are more likely to be cis eQTLs [20], we searched
for enrichment for eQTLs in our list of SNPs with pGWAS ,0.05.
We first determined the number of cis eQTLs in the set of SNPs
with pGWAS ,0.05 (n= 755). Then, we randomly selected a subset
of 14,167 SNPs with pGWAS .0.05, matched for minor allele
frequency to the set of SNPs with pGWAS ,0.05 (in 5% frequency
bins). Subsequently, we determined the number of eQTLs present
in each of these sets of SNPs, using 100,000 permutations. By
determining how often more than the initial number of eQTLs
were observed, we showed that there was evidence for enrichment
for eQTLs in the set of disease-associated SNPs (empirical
p = 0.003).
eQTL Replication
The eQTL replication set comprised 161 ALS patients and 206
control samples (Table S1). 951 out of 1,108 selected SNP-
transcript pairs in cis were significantly replicated (Figure 1). The
eQTL SNPs of these SNP-transcript pairs were selected for
replication in the GWAS replication data.
GWAS Replication
After quality control, there were 1,307 ALS cases and 1,835
controls in the GWAS replication set with genotypes for
266,492 SNPs (Table S2). 577 cis eQTL SNPs were tested for
association in the GWAS replication data. Using linkage
disequilibrium-based clumping of association results [28], 322
independent clumps could be formed. This number of clumps was
used for Bonferroni correction, as these clumps designate
independent loci. Table 1 shows clumps with a nominal pGWAS
,0.05 in the replication set. Ultimately, we identified 1 cis eQTL,
comprising 8 SNP-transcript pairs, which was significantly repli-
cated, and the transcript of which mapped to gene CYP27A1. The
results for this locus are listed in Table S3, also indicating that the
explained variance of gene expression that is achieved by the
linear models ranged from 48–65%. The relationships between the
SNPs and gene-expression levels are shown in Figure S3.
Fine-mapping of Loci UNC13A and Chromosome 9p21.2
In addition to our genome-wide screen for eQTLs associated
with sporadic ALS, we specifically examined possible relevant cis
effects in two previously associated loci (gene UNC13A and
chromosome 9p21.2) [7,12]. The detection of cis effects might fine-
map these loci. For the UNC13A locus (SNP rs12608932),
multiple-testing correction was applied for 41 possible SNP-
transcript pairs in cis (as determined by a genomic distance of
,500kb between the SNP and a probe’s midpoint). One SNP-
transcript pair had a nominal p value ,0.05, the transcript of
which mapped to gene PGLS (pEQTL= 0.01). However, when
using a 5% Benjamini-Hochberg FDR for the locus as multiple-
testing correction, no SNP-transcript pairs reached statistical
significance. For the chromosome 9p21.2 locus, we looked for cis
eQTLs within a 130kb LD block comprising previously associated
SNPs (rs2814707 and rs3849942). Multiple-testing correction for
the testing of 328 SNP-transcript pairs was applied using a 5%
FDR. Two SNP-transcript pairs reached the threshold for
statistical significance and were associated with C9orf72 isoform a
expression levels (Table 2 and Figure S4). SNP rs1565948
modulated C9orf72 gene expression in both eQTL discovery and
replication sets and was associated with susceptibility to ALS in the
joint GWAS data; however, no association with ALS was found in
the GWAS replication set alone (Table 2).
Discussion
The present study reports the results of a large and
comprehensive genome-wide screening of the genetics of gene
expression in an attempt to find novel genetic variants that
associate with sporadic ALS. We used a two-stage approach to
minimize the chance of false-positive findings, both for eQTL
discovery purposes and for the detection of novel SNP-ALS
associations. eQTLs were used for prioritizing GWAS results, as it
has been established that SNPs that are truly associated with
disease are more likely to be eQTLs [20,25,37]. In the present
study, we show that the number of eQTLs is greater than expected
by chance (p = 0.003) among the SNPs with a nominal association
with ALS, compared to frequency-matched SNPs, also indicating
that eQTLs may be useful in the prioritization of GWAS results in
ALS. We identified eight SNPs in one cis eQTL, modulating
CYP27A1 gene expression levels, which replicated in the second
eQTL dataset and second GWAS set. The eQTL SNPs within this
locus are part of a large linkage disequilibrium (LD) block
comprising a total of ten genes (Figure 2). The figure clearly shows
that the strongest eQTL associations exist for SNPs modulating
CYP27A1 expression, explaining up to 65% of variation in gene
expression of this gene. Additionally, we show that C9orf72 appears
to be the only gene in the 9p21.2 locus that is regulated in cis,
showing the potential of this approach in identifying causative
genes in association loci in ALS.
As shown in Table S3, the SNPs modulating transcript levels
had small effect sizes in our joint GWAS association results, the
Mapping of Gene Expression in Sporadic ALS
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highest odds ratio (OR) being 1.13. We used PS v3.0 [38] for
statistical power calculations to determine the required sample size
for a third genotypic replication of such SNPs. In order to replicate
an association for one SNP with minor allele frequency 0.35 at
a=0.05, one would require a minimum of 2,250 cases and 2,250
controls to achieve 80% power for detecting an effect with OR
1.13. As shown in Table 1, several eQTL SNPs did not reach
Bonferroni corrected significance in the replication data alone, but
do show stronger effects in the joint GWAS data, indicating that
statistical power of the GWAS replication set might be a limiting
factor. By testing these SNPs in a third independent replication
cohort, additional true associations may be detected. The required
sample size for such an effort would, however, increase
dramatically when adding more tests. Further international
collaboration, therefore, is needed in order to achieve sufficient
statistical power for the replication of SNPs with small effect sizes.
We searched MEDLINE, Gene Ontology and OMIM
databases to identify links to known pathways in ALS pathogenesis
for CYP27A1. The CYP27A1 gene is involved in cholesterol
metabolism and has been associated with cerebrotendinous
xanthomatosis (CTX), which can present with progressive upper
motor neuron signs and is a known clinical mimic for primary
lateral sclerosis [39,40]. Two heterozygous mutations in CYP27A1
have been reported in a patient with atypical CTX and
frontotemporal dementia characteristics [41]. Furthermore, pre-
viously, serum cholesterol levels have been implicated in modifying
survival and in the onset of respiratory impairment in ALS patients
[42–44]. The combination of our results and these prior data make
CYP27A1 a plausible candidate gene for ALS.
The strengths of our study are the meticulous pruning of
expression probes as present on the expression array, with regard
to non-specific mapping in the human transcriptome, or harboring
SNPs that might interfere with hybridization of probes to the
array, resulting in false-positive eQTLs [33]. In addition,
permutation schemes were applied, preserving the LD structure
within subjects, also minimizing the detection of false-positive
eQTLs. Finally, a two-stage approach, both for eQTLs discovery
purposes and for the detection of novel SNP-ALS associations,
ensures robustness of the results.
A drawback of the present study lies in the use of whole blood
instead of neuronal tissue for the measurement of mRNA
expression levels. As neuronal tissue is inaccessible in living ALS
patients, one could consider the use of human neuronal tissue from
autopsy. However, in post-mortem material of ALS patients, most
affected motor neurons will have degenerated and one would be
investigating exclusively end-stage disease expression profiles. We
have investigated the proportion of overlapping eQTLs between
our study and other studies, including two studies on human brain
tissue (Table S4) [24,26,45,46]. Studies of the genetics of gene
expression appear to have modest overlap in the eQTLs identified.
For example, 36.1% of genes mapped by a cis eQTL in
lymphocytes were identified in a study using lymphoblastoid cell
lines [24,45]. A smaller overlap (22%) was found between two
studies on brain tissue, which may partly be due to low statistical
power [26,46]. In the present study, 37 – 52% of the genes
mapped by cis eQTLs in human brain tissue studies appeared to
be present in our data (Table S4). The proportion of overlap with
studies on blood-derived tissues was comparable (41 – 45%).
Considering the relatively high concordance of genes mapped by
cis eQTLs in our screen with those found in human brain tissue,
we consider blood to be a valid starting point for genetic mapping
of gene expression in ALS. A large collection of central nervous
system tissue control samples may, however, further boost the
discovery of novel genetic variants that are associated with ALS.
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The focused analysis of variants in the chromosome 9p21.2
locus, which was previously associated with ALS [7,12], did not
identify rs2814707 or rs3849942 as eQTL SNPs. We did,
however, find evidence of two other SNPs (rs10122902 and
rs1565948), located within a large LD block surrounding the
previously associated markers, to be correlated with altered
expression levels of C9orf72 isoform a. SNP rs1565948 was
associated with ALS in our joint GWAS data. The rs10122902
variant was not associated with ALS in our joint GWAS, but was
previously shown to be part of a haplotype with rs3849942, in
which the major allele of rs10122902 was associated with
increased risk of ALS [12]. Genetic variation in the chromosome
9p21.2 locus, therefore, appears to be associated with altered
gene expression of C9orf72. The recent discovery of the intronic
hexanucleotide repeat expansion in C9orf72 on a common
haplotype in 9p21.2 linked families with ALS and FTD
[15,16,47] thus illustrates the potential of the combined use of
gene expression and genotyping in search for causative genes in
human diseases. The mechanism though of the recently
discovered repeat expansion in C9orf72 remains to be estab-
lished. There could be a direct effect of expression levels of
isoforms of C9orf72, or a ‘‘trans’’-like effect through RNA-
toxicity, as shown in other repeat expansions diseases including
fragile X-associated tremor/ataxia syndrome (FXTAS) [48].
Other types of experiments are needed to elucidate this
mechanism.
In summary, our genome-wide study of the genetics of gene
expression has identified one cis eQTL for sporadic ALS, which
modulates CYP27A1 expression and additionally points to C9orf72
in the chromosome 9p21.2 locus as the gene involved in ALS
pathogenesis. To further identify eQTLs relevant to ALS, the
concomitant analysis of epigenetic and other level -omic data, e.g.
proteomic or metabonomic can be used, as recently shown in a
model organism [49]. These studies are preferably performed in
‘ALS target tissues’, including post-mortem central nervous system
tissues and induced pluripotent stem cells differentiated to a
neuronal or glial lineage. Such studies may provide us with more
insight into novel pathogenic pathways and networks causal to this
devastating disease.
Supporting Information
Text S1 GWAS quality control.
(DOC)
Figure 2. Regional linkage disequilibrium (LD) near the CYP27A1 locus on chromosome 2. Top: the position of GWAS SNPs and RefSeq
genes located within the regional LD block are drawn. On the X-axis, genomic position in kb, aligned to NCBI genome build 36 coordinates. On the
left Y-axis, 2log10(p values) for the strongest cis eQTL association for a gene in the replication data, the vertical position of genes (drawn as arrows)
are aligned to this axis and thus represent statistical significance. For one gene (RQCD1), no SNP-transcript pair and, therefore, no eQTL p value was
available in our data. This gene is shown as a dashed arrow. On the right Y-axis, 2log10(p values) from the replication GWAS analysis for SNPs within
the region (black line), SNPs modulating CYP27A1 expression are shown as black dots, other SNPs are grey. Bottom: pairwise linkage disequilibrium
for HapMap phase III release 2 SNPs (CEU+TSI populations). The LD plot was created in Haploview v4.2 [50], using the standard D’/LOD color scheme.
doi:10.1371/journal.pone.0035333.g002
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Figure S1 Manhattan plot of autosomal SNP association
p values in the GWAS discovery set.
(PDF)
Figure S2 Quantile-quantile plot of observed 2log10 (p
values) versus the expectation under the null for the
genome-wide association results in the GWAS discovery
set.
(PDF)
Figure S3 Plots for SNP genotype vs. expression level
correlations for eQTL SNPs modulating CYP27A1 ex-
pression levels.
(PDF)
Figure S4 Plots for SNP genotype vs. expression level
correlations for eQTL SNPs modulating C9orf72 expres-
sion levels.
(PDF)
Table S1 Expression study populations.
(PDF)
Table S2 GWAS populations and genotyping platforms.
(PDF)
Table S3 Results for replicated eQTLs associated with
CYP27A1 expression levels.
(PDF)
Table S4 cis eQTL overlap with previous studies.
(PDF)
Table S5 Details of quality control of genome-wide
genotype data.
(PDF)
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